BOS Asset Management LLC bought a new stake in Pfizer Inc. (NYSE:PFE – Get Rating) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 9,525 shares of the biopharmaceutical company’s stock, valued at approximately $488,000.
Several other large investors have also recently made changes to their positions in the company. Freedom Wealth Alliance LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $35,000. RF&L Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth $371,000. Brogan Financial Inc. acquired a new position in Pfizer during the fourth quarter worth $322,000. Axxcess Wealth Management LLC raised its position in Pfizer by 76.0% during the fourth quarter. Axxcess Wealth Management LLC now owns 119,819 shares of the biopharmaceutical company’s stock worth $6,140,000 after acquiring an additional 51,734 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec raised its position in Pfizer by 3.0% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 16,132,678 shares of the biopharmaceutical company’s stock worth $826,638,000 after acquiring an additional 466,641 shares during the period. 67.62% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Trading Up 1.0 %
Shares of PFE opened at $40.30 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.31. Pfizer Inc. has a 12-month low of $36.17 and a 12-month high of $54.93. The firm has a 50-day moving average price of $39.07 and a 200 day moving average price of $43.24. The firm has a market capitalization of $227.51 billion, a P/E ratio of 7.93, a P/E/G ratio of 1.29 and a beta of 0.64.
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The firm had revenue of $18.28 billion during the quarter, compared to analyst estimates of $16.49 billion. During the same quarter in the prior year, the firm posted $1.62 earnings per share. Pfizer’s quarterly revenue was down 28.8% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 3.35 EPS for the current year.
Pfizer Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, June 9th. Shareholders of record on Friday, May 12th were paid a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 4.07%. The ex-dividend date of this dividend was Thursday, May 11th. Pfizer’s dividend payout ratio (DPR) is presently 32.28%.
Insiders Place Their Bets
In related news, major shareholder Pfizer Inc bought 1,811,594 shares of the stock in a transaction on Friday, March 17th. The stock was bought at an average price of $2.76 per share, with a total value of $4,999,999.44. Following the completion of the purchase, the insider now directly owns 5,952,263 shares in the company, valued at approximately $16,428,245.88. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Pfizer Inc bought 1,811,594 shares of the stock in a transaction on Friday, March 17th. The stock was bought at an average price of $2.76 per share, with a total value of $4,999,999.44. Following the completion of the purchase, the insider now directly owns 5,952,263 shares in the company, valued at approximately $16,428,245.88. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Monday, May 8th. The stock was acquired at an average cost of $38.58 per share, with a total value of $38,580.00. Following the purchase, the director now owns 6,000 shares of the company’s stock, valued at approximately $231,480. The disclosure for this purchase can be found here. Insiders purchased a total of 1,813,594 shares of company stock valued at $5,076,999 over the last 90 days. 0.05% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on PFE shares. UBS Group reduced their price objective on shares of Pfizer from $41.00 to $39.00 in a research report on Friday, May 5th. Morgan Stanley reduced their price objective on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating for the company in a research report on Monday, April 10th. Barclays reduced their price objective on shares of Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. JPMorgan Chase & Co. set a $45.00 target price on shares of Pfizer in a research report on Monday, February 27th. Finally, Jefferies Financial Group initiated coverage on shares of Pfizer in a research report on Monday, March 6th. They issued a “hold” rating and a $43.00 target price for the company. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $47.33.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.